We are live on ! Find out more

Cytosorbents Corp

CTSO

Market cap $19.1M

6.06 USD

-0.01

0.16%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

6.24

+0.18

2.97%

1 day

-0.16%

5 days

-10.09%

1 month

-19.63%

3 months

-29.86%

6 months

-53.38%

Year to date

-53.81%

1 year

-66.9%

5 years

-96.3%

10 years

-95.32%

About: CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.

Employees: 129

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference

PRINCETON, N.J., Sept. 10, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming H.C.

CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference

CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Princeton, New Jersey--(Newsfile Corp. - September 4, 2026) - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026, in New York City. Dr. Phillip Chan, CEO and Peter Mariani, CFO will be attending the conference, delivering an investor presentation and participating in scheduled 1-on-1 meetings with investors.

CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

CytoSorbents Announces Reverse Stock Split

Reverse Stock Split Previously Approved by Shareholders; Intended to Support Compliance with Nasdaq's $1.00 Minimum Bid Price Requirement Expected to Become Effective and Trade on Split-Adjusted Basis at the Market Open on September 8, 2026 PRINCETON, N.J., Sept. 3, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it will effect a one-for-twenty (1:20) reverse stock split (the "Reverse Stock Split") of its common stock, par value $0.001 per share (the "Common Stock").

CytoSorbents Announces Reverse Stock Split

CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings

Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen, with no serious device-related adverse events reported Findings reinforce results from the STAR-T trial and are expected to form a core component of additional real-world evidence planned for a new U.S. FDA De Novo submission for DrugSorb-ATR® Recent FDA Pre-Submission meetings provided constructive feedback on potential U.S. regulatory pathways for DrugSorb-ATR for separate applications for ticagrelor and direct oral anticoagulant removal in urgent cardiac surgery PRINCETON, N.J., Sept. 2, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced an independent new patient-level matched analysis of real-world data demonstrating that intraoperative use of CytoSorb was associated with a significant reduction in severe perioperative bleeding among patients undergoing urgent coronary artery bypass grafting (CABG) surgery on the blood thinner, ticagrelor (Brilinta®/Brilique®, AstraZeneca).

CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings

Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call Transcript

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., Aug. 6, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2026, recent business highlights, and provides a regulatory update.

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights

PRINCETON, N.J., July 20, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2026 financial results and recent business highlights after the market close on Thursday, August 6, 2026.

CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights

CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026

PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Life Sciences Forum hosted by VirtualInvestorConferences.com on Wednesday, June 24, 2026 and provide an overview and update on the Company. Following the presentation, Zacks Analyst Mr. Thomas Kerr will host a brief Q&A session with Dr. Chan and Mr. Peter Mariani, Chief Financial Officer.

CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026

Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript

Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript

Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript

CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

PRINCETON, N.J., May 13, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2026, recent business highlights, and provides a regulatory update.

CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

See News Rankings

Price charts implemented using Lightweight Charts™